As of Jun 02
| +0.095 / +3.42%|
The 3 analysts offering 12-month price forecasts for Kezar Life Sciences Inc have a median target of 15.00, with a high estimate of 19.00 and a low estimate of 13.00. The median estimate represents a +421.74% increase from the last price of 2.88.
The current consensus among 6 polled investment analysts is to Buy stock in Kezar Life Sciences Inc. This rating has held steady since March, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.